Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
about
Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk predictionRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancerPrediction of individual response to anticancer therapy: historical and future perspectivesThe Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.Oxidative stress promotes myofibroblast differentiation and tumour spreading.Does lapatinib work against HER2-negative breast cancers?Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan.The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer.Hormone receptor expression in breast cancer: postanalytical issues.Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.Expression of activated type I receptor tyrosine kinases in early breast cancer.Rituximab for the treatment of follicular lymphoma.Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome.Reliability of receptor assessment on core needle biopsy in breast cancer patients.microRNA-10b expression and its correlation with molecular subtypes of early invasive ductal carcinoma.Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience.Reduced risk of axillary lymphatic spread in triple-negative breast cancer.Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients
P2860
Q33847811-A2396A05-093A-4152-ACDA-F7AD982E6C03Q33862786-4C46853F-1701-4169-847B-40442D17012AQ34126938-FE897883-E212-434D-81E3-054D7C761F42Q35024682-302F1E60-CE15-47FC-AC29-81ACF6C15FC8Q35948882-5F1F91D1-5450-44F3-A544-EE5863455A87Q36039273-1826DECE-56E3-4556-BC3F-90621F2C8288Q36253050-EE73FCA8-5E38-4F82-80B1-FA79BA2F9A1CQ36489321-4D082F97-7F61-4129-B6BC-B38964951E0EQ36761689-B270A26E-7B8B-4BB4-B9E2-B4F1EFCCF0F7Q36806619-543DBE22-5B4D-4ABF-926F-4364407B90C0Q37240710-AECD6B21-0E9E-4A3D-8DD2-7DB045741BC6Q37308228-A7534944-FFF7-40E1-A9AD-F7B035880829Q37755092-CEE453B4-9831-416F-BE59-A05409FE9992Q38092775-31D3F6B5-7624-4E92-A4D4-E30BBB063BDEQ38454847-B15A38BF-7C75-4CC0-AA8D-7594CF934BA9Q38458901-8065C9C0-A8E8-4F12-9BC2-9C18D90B2068Q39360775-0BC84C5F-6D07-41DB-9511-F1B4566FD9B5Q41205623-BE350F50-DD4A-419A-A8A9-70D16F59170CQ42489900-F8997C9E-4442-4A8A-B0F1-161745C4DA05Q50768830-48FE5DDD-BF4C-494B-90E9-0456767D6471Q52620485-7F8BDCD9-52C8-4C87-BF34-6F2827B33845Q53825199-F8543EBF-503E-40FF-A4FD-50AE06D1DD54Q54303283-78E3DFB5-6EC8-4B5E-8510-FAB50D73BD8DQ54378040-F8D17F90-FF4C-485F-AAB5-B0E6A04B8931Q54601565-640A064E-0002-4628-9A53-B0A20EA9ACC7Q58703254-628FA30E-B886-49DC-B738-71DE4E6BBC25
P2860
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Human epidermal growth factor ...... le for cytotoxic chemotherapy.
@en
Human epidermal growth factor ...... le for cytotoxic chemotherapy.
@nl
type
label
Human epidermal growth factor ...... le for cytotoxic chemotherapy.
@en
Human epidermal growth factor ...... le for cytotoxic chemotherapy.
@nl
prefLabel
Human epidermal growth factor ...... le for cytotoxic chemotherapy.
@en
Human epidermal growth factor ...... le for cytotoxic chemotherapy.
@nl
P2093
P50
P921
P356
P1476
Human epidermal growth factor ...... le for cytotoxic chemotherapy.
@en
P2093
Clare Peckitt
David A Cameron
Elizabeth A Mallon
John M S Bartlett
Judith M Bliss
Lindsay Johnson
Paul Ellis
Roger A'Hern
Stephen Johnston
P304
P356
10.1200/JCO.2007.11.0973
P407
P577
2007-10-01T00:00:00Z